Paper: Translation of inhaled exposure throughout drug development: A case-study on how to de-risk formulation development and secure clinical exposure
Dr. Rebecca Fransson is an Associate Director within Advanced Drug Delivery, Pharmaceutical Sciences at AstraZeneca in Gothenburg, Sweden. Rebecca joined AstraZeneca in 2014 and has since then been supporting drug projects with inhaled biopharmaceutics assessments. In her research she has been focusing on dissolution and delivery of inhaled drug products. She has also worked with and contributed to the development of Lung-SIM, an in silico tool for physiologically based biopharmaceutics predictions for inhaled drug delivery. Currently she is leading a team of experts in biopharmaceutics supporting oral and inhaled projects from the pre-clinical stage up to phase 2 clinical development.
rior to joining AstraZeneca, Rebecca earned her PhD in medicinal chemistry from University of Uppsala and held an academic post-doc position in the field of medicinal chemistry at University of Montreal and a research position at University of Uppsala.